1-20 of 144 results for house:"House of Lords"
Librarians' tools
- Search time
- 0.492 seconds
- Solr query time
- 0.014 seconds
- Search query
- house:"House of Lords"
- We searched for
- legislature_ses:25277
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty's Government how many, and what percentage of the total of, (1) care home residents, (2) care home staff, (3) frontline health workers, and (4) patients over 80, have been vaccinated against COVID-19 in (a) England, (b) Scotland, (c) Wales, and (d) Northern Ireland.
To ask Her Majesty's Government how many, and what percentage of the total of, (1) care home residents, (2) care home staff, (3) frontline health workers, and (4) patients over 80, have been vaccinated against COVID-19 in (a) England, (b) Scotland, (c) Wales, and (d) Northern Ireland.
NHS England releases weekly vaccination data which shows that as of 15 April:
- 94.2% eligible residents in older adult care homes in England have received at least their first dose of a COVID-19 vaccine;
- 79.4% eligible staff in older adult resident care homes have received at least their first dose; and
- 95.2% of patients over 80 years old have received at least their first dose of a COVID-19 vaccine.
The percentage of National Health Service trust health care workers who have received at least their first dose is not currently available, as NHS England’s data does not currently include all frontline health workers as a sub-group.
COVID-19 vaccination data for Scotland, Wales and Northern Ireland is not collected centrally in the format requested as this is a devolved matter.
To ask Her Majesty's Government how many people in total were vaccinated against COVID-19 in the UK using (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, vaccine in each week since the beginning of 1 December 2020.
To ask Her Majesty's Government how many people in total were vaccinated against COVID-19 in the UK using (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, vaccine in each week since the beginning of 1 December 2020.
The information is not collected in the format requested.
To ask Her Majesty's Government what assurances AstraZeneca gave about its commitment to manufacture the Oxford vaccine prior to either (1) a successful testing programme, or (2) approval by the Medicines and Healthcare products Regulatory Agency.
To ask Her Majesty's Government what assurances AstraZeneca gave about its commitment to manufacture the Oxford vaccine prior to either (1) a successful testing programme, or (2) approval by the Medicines and Healthcare products Regulatory Agency.
Assurances agreed between the Government and Oxford/AstraZeneca are bound by commercially confidential contracts.
My Lords, this order, with its 10p charge, will have little effect on a huge problem that is well known to this Minister, with his long and admirable track record on the environment.
I have a single question, which I have already notified to the Minister’s officials. Why do we not...
My Lords, this order, with its 10p charge, will have little effect on a huge problem that is well known to this Minister, with his long and admirable track record on the environment.
I have a single question, which I have already notified to the Minister’s officials. Why do we not...
To ask Her Majesty's Government whether the requirements of the contract they awarded to Wockhardt Ltd, to help in the production of COVID-19 vaccines, are currently being fulfilled.
To ask Her Majesty's Government whether the requirements of the contract they awarded to Wockhardt Ltd, to help in the production of COVID-19 vaccines, are currently being fulfilled.
The Oxford/AstraZeneca vaccine is currently being filled and finished at the Wockhardt site.
The Government has recently extended Wockhardt’s contract from 18 to 24 months to ensure that we have uninterrupted capability into 2022. Specific details of contract fulfillment are commercially sensitive.
To ask Her Majesty's Government what estimate they have made of the duration of protection from COVID-19 provided by (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, vaccine; and what estimate they have made of the length of time a person who receives (a) only a first dose, and (b) two...
To ask Her Majesty's Government what estimate they have made of the duration of protection from COVID-19 provided by (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, vaccine; and what estimate they have made of the length of time a person who receives (a) only a first dose, and (b) two...
The total length of protection from vaccines against COVID-19 is not yet fully understood. Vaccine developers and manufacturers continue to collect data on the performance of their vaccines. Through their surveillance strategy Public Health England (PHE) continues to assess the effectiveness of vaccines, including duration of protection. A copy of PHE’s COVID-19 vaccine surveillance Strategy is attached.
On 26 January the Joint Committee on Vaccine and Immunisation (JCVI) published an online report, Optimising the COVID-19 vaccination programme for maximum short-term impact. The report found that short-term vaccine efficacy from the first dose of the Pfizer/BioNTech vaccine is calculated at around 90% and from the first dose of the Oxford/ AstraZeneca vaccine is calculated at around 70%, with high protection against severe disease.
Given the high level of protection afforded by the first dose, models suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalisations than vaccinating a smaller number of people with two doses. The second dose is important to provide longer lasting protection and is expected to be as or more effective when delivered at an interval of 12 weeks from the first dose. The JCVI has based their advice on the assumption that protection from a first dose of either vaccination will wane in the medium term and that a second dose will offer more long term protection.
To ask Her Majesty's Government what is the optimum gap between the first and second dose of (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, COVID-19 vaccine for securing the longest period of protection against COVID-19.
To ask Her Majesty's Government what is the optimum gap between the first and second dose of (1) the Oxford/AstraZeneca, and (2) the Pfizer/BioNTech, COVID-19 vaccine for securing the longest period of protection against COVID-19.
The Medicines and Healthcare products Regulatory Agency’s (MHRA’s) Information for Healthcare Professionals regarding the Pfizer vaccine states that a second dose of it should be given at least 21 days after the first dose. For the AstraZeneca vaccine, the Information for Healthcare Professionals states that the second dose should be given between four and 12 weeks after the first dose. This advice is based on clinical trial data and other information submitted to MHRA by the manufacturer.
Based on trial data showing the effectiveness of both vaccines, the Joint Committee on Vaccination and Immunisation (JCVI) advised that both vaccines should be given up to 12 weeks apart. The JCVI also advised that priority should be given to having a greater number of people given a first dose, which would have a greater public health impact than prioritising second doses.
To ask Her Majesty's Government what assessment they have made of (1) the quantity of glass vials that will be needed to distribute COVID-19 vaccines, (2) the capacity to manufacture these vials, and (3) any procurement or delivery issues that may arise.
To ask Her Majesty's Government what assessment they have made of (1) the quantity of glass vials that will be needed to distribute COVID-19 vaccines, (2) the capacity to manufacture these vials, and (3) any procurement or delivery issues that may arise.
The procurement of vials is the responsibility of the manufacturer and the United Kingdom Government has actively engaged with each manufacturer regarding manufacturing capacity, procurement and delivery to ensure enough stock is available, providing additional support where required. The UK has a sufficient number of glass vials available, due to orders already placed with manufacturers.
To ask Her Majesty's Government, further to the abolition of the Northwest Regional Development Agency on 31 March 2012, what plans they have to publish documents previously held by that Agency relating to (1) the Agency’s funding of the University of Cumbria’s acquisition of Newton Rigg College in Cumbria, and...
To ask Her Majesty's Government, further to the abolition of the Northwest Regional Development Agency on 31 March 2012, what plans they have to publish documents previously held by that Agency relating to (1) the Agency’s funding of the University of Cumbria’s acquisition of Newton Rigg College in Cumbria, and...
The government has no plans to publish documents concerning the funding and transfer of assets and land relating to the University of Cumbria’s acquisition of Newton Rigg College in 2007.
My Lords, should we not congratulate the Mail and in particular journalist Stephen Wright for his forensic work in unravelling the Beech affair and their exposure of deficiencies in the Rodhouse-led investigations? Why does not Mr Rodhouse, who prior to the abuse scandals had a reputation for competence and thorough investigations, interview and explain the background to his actions? We all make mistakes in life and sometimes admitting them can be both therapeutic and clear the air. At least the public would then understand what has happened.
My Lords, should we not congratulate the Mail and in particular journalist Stephen Wright for his forensic work in unravelling the Beech affair and their exposure of deficiencies in the Rodhouse-led investigations? Why does not Mr Rodhouse, who prior to the abuse scandals had a reputation for competence and thorough investigations, interview and explain the background to his actions? We all make mistakes in life and sometimes admitting them can be both therapeutic and clear the air. At least the public would then understand what has happened.
My Lords, so far as the Mail’s investigations are concerned, I would make three points. First, the message must go out that if you deliberately lie about sexual abuse, you will go
to prison for a long time—in this case, 18 years. Secondly, as the noble Lord said, people make mistakes. The MPS made mistakes, it has learned, it needed to learn, and it is continuing to learn. Thirdly, however, the message must go out: if you are a victim of child sex abuse, even if it is historic, come forward. We have successfully prosecuted and obtained over 5,000 convictions, and in every case we will seek to ensure that justice is done, whether that be a conviction or an acquittal.
My Lords, I strongly support the proposal from the noble Lord, Lord Rooker. I shall concentrate my remarks on inheritance taxes. The Budget statement proposes a freeze on nil-rate bands until April 2026. This means qualifying estates can pass on up to £500,000, and the qualifying estate of a surviving...
My Lords, I strongly support the proposal from the noble Lord, Lord Rooker. I shall concentrate my remarks on inheritance taxes. The Budget statement proposes a freeze on nil-rate bands until April 2026. This means qualifying estates can pass on up to £500,000, and the qualifying estate of a surviving...
To ask Her Majesty's Government what assessment they have made of whether the acquisition of Newton Rigg College in Cumbria by Askham Bryan College in York in 2011 met their standards of propriety in public sector procurement; and what plans they have, if any, to review the negotiation process that...
To ask Her Majesty's Government what assessment they have made of whether the acquisition of Newton Rigg College in Cumbria by Askham Bryan College in York in 2011 met their standards of propriety in public sector procurement; and what plans they have, if any, to review the negotiation process that...
Following the decision by the University of Cumbria in 2010, to cease delivering the provision of further education funded by the Skills Funding Agency and the Young People’s Learning Agency, the Skills Funding Agency led an open and competitive procurement process, in accordance with Part B of Schedule 3 of the Public Contracts Regulations 2006, to secure an alternative provider or providers for the delivery of arts provision in Carlisle and predominately land-based provision at Newton Rigg. As a result of this competition, the funding for students studying further education at the University’s Brampton Road building was transferred to Carlisle College, and the funding for students studying further education at Newton Rigg, together with the further education assets at Newton Rigg, was transferred to Askham Bryan College. The procurement was subject to a review by Cabinet Office in 2011 and its findings have been published on gov.uk and are attached.
The successor organisation to the Skills Funding Agency, the Education and Skills Funding Agency now procure provision in accordance with the requirements of the Public Contracts Regulations, 2015. In some circumstances, for example the provision of education and training for young people, separate arrangements apply, but processes and procedures are fair and transparent. Where this applies, we use a mix of local negotiation and tendering appropriate to the circumstances in each case.
On the issue of Covid vaccination policy for rough sleepers, is it not true that they are not treated nationally as a priority group for vaccination and that we have a postcode lottery in operation? Some areas treat them as a priority, others do not, yet they are a particularly...
On the issue of Covid vaccination policy for rough sleepers, is it not true that they are not treated nationally as a priority group for vaccination and that we have a postcode lottery in operation? Some areas treat them as a priority, others do not, yet they are a particularly...
Is it not true that if the Government had not blocked ID cards in 2011—a perfect form of vaccination passport—then we could have avoided problems about vaccination recording by entering annual vaccination data that would have been readable on the card chip, covered the entire population with a track-and-trace system, and, in effect, brought this nightmare of an epidemic to an earlier end? The Government missed a trick that could have saved billions of pounds and perhaps even thousands of lives.
Is it not true that if the Government had not blocked ID cards in 2011—a perfect form of vaccination passport—then we could have avoided problems about vaccination recording by entering annual vaccination data that would have been readable on the card chip, covered the entire population with a track-and-trace system, and, in effect, brought this nightmare of an epidemic to an earlier end? The Government missed a trick that could have saved billions of pounds and perhaps even thousands of lives.
My Lords, I note the noble Lord’s enthusiasm for ID cards, but it was not shared universally either in Parliament or outside. I am certainly not going there on this issue.
Why do the Government not require every local authority to publish the addresses of all buildings falling under cladding fire risk categories? Is the FOI response from the DCLG of 12 March last year refusing such information still valid where it spuriously states that
“disclosing it would be likely to endanger...
Why do the Government not require every local authority to publish the addresses of all buildings falling under cladding fire risk categories? Is the FOI response from the DCLG of 12 March last year refusing such information still valid where it spuriously states that
“disclosing it would be likely to endanger...
To ask Her Majesty's Government what assessment they have made of the effectiveness of the guidance included in the guideline by the National Institute for Health and Care Excellence Spondyloarthritis in over 16s: diagnosis and management, published on 28 February 2017.
To ask Her Majesty's Government what assessment they have made of the effectiveness of the guidance included in the guideline by the National Institute for Health and Care Excellence Spondyloarthritis in over 16s: diagnosis and management, published on 28 February 2017.
No specific assessment has been made.
The National Institute for Health and Care Excellence’s guidelines describe best practice but are not mandatory, although health and care commissioners are expected to take them fully into account.
To ask Her Majesty's Government what steps they are taking to implement the guideline by the National Institute for Health and Care Excellence Spondyloarthritis in over 16s: diagnosis and management, published on 28 February 2017.
To ask Her Majesty's Government what steps they are taking to implement the guideline by the National Institute for Health and Care Excellence Spondyloarthritis in over 16s: diagnosis and management, published on 28 February 2017.
No specific assessment has been made.
The National Institute for Health and Care Excellence’s guidelines describe best practice but are not mandatory, although health and care commissioners are expected to take them fully into account.
To ask Her Majesty's Government which Government departments have relationships with Askham Bryan College; and which Department has overall responsibility for policies towards that college.
To ask Her Majesty's Government which Government departments have relationships with Askham Bryan College; and which Department has overall responsibility for policies towards that college.
Askham Bryan College’s primary relationship with government is with the department and its executive agency, the Education and Skills Funding Agency. The department has overall responsibility for policies relating to the delivery of further education and higher education which are provided by Askham Bryan College.
My Lords, to follow up on the interesting question from the noble Baroness, Lady Deech, is there not a compromise? If the problem is a requirement for a sibling to sell a jointly owned and occupied property to pay IHT, why not simply defer the deceased’s liability, thereby leaving the surviving sibling undisturbed? The taxman would ultimately be paid. This could be done on the basis of a charge on the property, perhaps even tapered in favour of the Revenue or the surviving sibling, dependent on tax rate policy.
My Lords, to follow up on the interesting question from the noble Baroness, Lady Deech, is there not a compromise? If the problem is a requirement for a sibling to sell a jointly owned and occupied property to pay IHT, why not simply defer the deceased’s liability, thereby leaving the surviving sibling undisturbed? The taxman would ultimately be paid. This could be done on the basis of a charge on the property, perhaps even tapered in favour of the Revenue or the surviving sibling, dependent on tax rate policy.
My Lords, to add to my previous answer, for those in certain circumstances, joint ownership would also mean that a house had to exceed £650,000—more than the average house price, including in London—to be liable for inheritance tax. As I say, there are arrangements in place whereby you can have up to 10 years to pay off inheritance tax in instalments if the estate contains an unsold house.
To ask Her Majesty's Government, further to the Written Answer by Lord Callanan on 21 January (HL11869), with which companies they have entered into any contracts relating to the production of COVID-19 vaccines; and what plans they have to make the terms of those contracts available to the public.
To ask Her Majesty's Government, further to the Written Answer by Lord Callanan on 21 January (HL11869), with which companies they have entered into any contracts relating to the production of COVID-19 vaccines; and what plans they have to make the terms of those contracts available to the public.
The UK Government has secured early access to 457 million vaccines doses through agreements with eight separate vaccine developers. This includes agreements with BioNTech/Pfizer, University of Oxford/AstraZeneca, GlaxoSmithKline/Sanofi Pasteur, Novavax, Janssen, Valneva, Moderna and CureVac.
In addition to the above, we have also funded fill and finish capability through a contract with Wockhardt in Wrexham, North Wales, as well as the expansion of the Valneva factory in Livingston, Scotland.